Dr. A. Louis Bourgeois

• 
  www.acebiosciences.com/joomla/index.php?view=article&ca - [Cached Version]
  Published on: 3/2/2006    Last Visited: 4/21/2008  

  ACE BioSciences A/S, the infectious diseases company is pleased to announce that it has appointed a prestigious Vaccine Scientific Advisory Board comprising: Dr Jerry Sadoff, President and Chief Executive Officer of the Aeras Global TB Vaccine Foundation, US; Dr A Louis Bourgeois, Associate Research Professor, Center for Immunization Research at the Johns Hopkins University Bloomberg School of Public Health, US; and Dr David Lewis, Professor of Clinical Vaccinology and Medicine, Department of Cellular Molecular Medicine (Centre for Infection), at St George's, University of London, UK.
  ...
  Dr Bourgeois has nearly 30 years international experience in infectious disease research.Over the last six years he has served as a Principal and Associate Investigator on Clinical Trials evaluating vaccine candidates for ETEC diarrhea, Shingella dysentery and Typhoid Fever.He has also led field teams evaluating the protective efficacy of an ETEC vaccine in travellers to Central America and Mexico and new antibiotics for the treatment of Traveller's diarrhoea among international visitors to this region.Prior to joining Johns Hopkins University, he was a member of the US Navy's Enteric Diseases Research Programme, where he worked on Campylobacter vaccine and mucosal adjuvant development.

• 
  www.employment-inc.com/v-cgi/feeds.cgi?feedid=136&story - [Cached Version]
  Published on: 11/10/2004    Last Visited: 12/18/2005  

  "This is a very encouraging first step," said microbiologist A. Louis Bourgeois of Johns Hopkins University's Bloomberg School of Public Health, who led the study of the Swedish-developed vaccine.
  ...
  At first the vaccine appeared only to lessen disease severity, Bourgeois said.
  ...
  Bourgeois said the vaccine's developers are working to improve that.
  
  "Obviously this is not the final product, but this needs to be pursued," Bourgeois said, noting that a workable travelers' vaccine might help the harder goal of protecting children in developing countries who die from the germ.

• 
  www.audiomedica.com/index.php?tag=e.coli - [Cached Version]
  Published on: 1/10/2005    Last Visited: 11/30/2006  

  Louis Bourgeois, Johns Hopkins University, Baltimore

• 
  ACE BioSciences A/S - [Cached Version]
  Published on: 3/10/2008    Last Visited: 3/10/2008  

  Dr. A. Louis BourgeoisAssociate Research Professor, CIRCenter for Immunization Research, Department of International Health, Baltimore, USA
  ...
  Dr. Bourgeois has nearly 30 years international experience in infectious disease research.Over the last six years he has served as a Principal and Associate Investigator on Clinical Trials evaluating vaccine candidates for ETEC diarrhoea, Shigella dysentry and Typhoid Fever.He has also led field teams evaluating the protective efficacy of an ETEC vaccine in travellers to Central America and Mexico and new antibiotics for the treatment of Traveller's Diarrhoea aming international visitors to this region.Prior to joining Johns Hopkins University, he was a member of the US Navy's Enteric Diseases Research Programme, where he worked on Campylobacter vaccine and mucosal adjuvant development.

• 
  ACE BioSciences A/S - [Cached Version]
  Published on: 3/2/2006    Last Visited: 2/29/2008  

  2 March 2006 -- ACE BioSciences A/S, the infectious diseases company is pleased to announce that it has appointed a prestigious Vaccine Scientific Advisory Board comprising: Dr Jerry Sadoff, President and Chief Executive Officer of the Aeras Global TB Vaccine Foundation, US; Dr A Louis Bourgeois, Associate Research Professor, Center for Immunization Research at the Johns Hopkins University Bloomberg School of Public Health, US; and Dr David Lewis, Professor of Clinical Vaccinology and Medicine, Department of Cellular Molecular Medicine (Centre for Infection), at St George's, University of London, UK.
  ...
  Dr Bourgeois has nearly 30 years international experience in infectious disease research.Over the last six years he has served as a Principal and Associate Investigator on Clinical Trials evaluating vaccine candidates for ETEC diarrhea, Shingella dysentery and Typhoid Fever.He has also led field teams evaluating the protective efficacy of an ETEC vaccine in travellers to Central America and Mexico and new antibiotics for the treatment of Traveller's diarrhoea among international visitors to this region.Prior to joining Johns Hopkins University, he was a member of the US Navy's Enteric Diseases Research Programme, where he worked on Campylobacter vaccine and mucosal adjuvant development.

• 
  Citizens State Bank of Clara City - [Cached Version]
  Published on: 12/18/2005    Last Visited: 12/18/2005  

  "This is a very encouraging first step," said microbiologist A. Louis Bourgeois of Johns Hopkins University's Bloomberg School of Public Health, who led the study of the Swedish-developed vaccine.
  ...
  At first the vaccine appeared only to lessen disease severity, Bourgeois said.
  ...
  Bourgeois said the vaccine's developers are working to improve that.

• 
  ETEC Phase I trial - [Cached Version]
  Published on: 3/29/2000    Last Visited: 11/23/2004  

  Commenting on the trial, Principal Investigator, Dr Lou Bourgeois, Head of the Vaccine Testing Unit at Johns Hopkins University, said: "Our clinical research team was extremely impressed by the substantial mucosal immunogenicity of these attenuated vaccine constructs and by the higher than expected antibody responses achieved in serum by the more immunogenic of the two constructs.

• 
  FSnet Dec. 18/05 - [Cached Version]
  Published on: 12/18/2005    Last Visited: 5/11/2006  

  Microbiologist A. Louis Bourgeois of Johns Hopkins University's Bloomberg School of Public Health, who led the study of the Swedish-developed vaccine, was quoted as saying, "This is a very encouraging first step."

• 
  ICAAC: Vaccine in Works to Block Traveler's Diarrhea -... - [Cached Version]
  Last Visited: 4/22/2006  

  "We feel this is a very promising concept for a vaccine for traveler's diarrhea," said A. Louis Bourgeois, Ph.D., of the Center for Immunization Research at the Johns Hopkins Bloomberg School of Public Health.
  
  The vaccine is targeted against the major cause of traveler's diarrhea, enterotoxigenic Escherichia coli, Dr. Bourgeois and colleagues reported at the Interscience Conference on Antimicrobial Agents and Chemotherapy.
  
  They administered it to more than 700 students on their way to Spanish- language immersion classes in Guatemala and Mexico.Another 700 participants were given placebo.
  
  The vaccine contains formalin-killed E. coli whole cells plus the B-subunit of the cholera enterotoxin.The vaccine is taken in a two-dose regimen seven to 21 days apart.Not surprisingly, Dr. Bourgeois said that traveler's who mounted the strongest response to introduction of the vaccine were best protected.If, on arrival in the place of study a patient had immunoglobulin A titers to E. coli that were more than 1,358 it was assumed that the vaccine had "taken."
  
  Of the 700 people who were given the active agent, 156 developed sufficient responses to have been considered vaccinated, Bourgeois said.They were matched against 195 of the placebo students.
  
  Among this subgroup, he said, the vaccine was about 77% effective in preventing diarrhea in the students, and even among those students who came down with E. coli -caused diarrhea; the cases were relatively mild compared to those who were taking the placebo.
  ...
  Dr. Bourgeois is working in collaboration with Johns Hopkins and SBL Vaccines of Solna, Sweden, on the vaccine."The further development of this promising enterotoxigenic E. Coli vaccine is warranted and should be pursued," he said.

• 
  March 2nd, 2006 - ACE BIOSCIENCES APPOINTS PRESTIGIOUS... - [Cached Version]
  Published on: 3/2/2006    Last Visited: 6/5/2009  

  ACE BioSciences A/S, the infectious diseases company is pleased to announce that it has appointed a prestigious Vaccine Scientific Advisory Board comprising: Dr Jerry Sadoff, President and Chief Executive Officer of the Aeras Global TB Vaccine Foundation, US; Dr A Louis Bourgeois, Associate Research Professor, Center for Immunization Research at the Johns Hopkins University Bloomberg School of Public Health, US; and Dr David Lewis, Professor of Clinical Vaccinology and Medicine, Department of Cellular Molecular Medicine (Centre for Infection), at St George's, University of London, UK.
  ...
  Dr Bourgeois has nearly 30 years international experience in infectious disease research. Over the last six years he has served as a Principal and Associate Investigator on Clinical Trials evaluating vaccine candidates for ETEC diarrhea, Shingella dysentery and Typhoid Fever. He has also led field teams evaluating the protective efficacy of an ETEC vaccine in travellers to Central America and Mexico and new antibiotics for the treatment of Traveller's diarrhoea among international visitors to this region. Prior to joining Johns Hopkins University, he was a member of the US Navy's Enteric Diseases Research Programme, where he worked on Campylobacter vaccine and mucosal adjuvant development.

Page:  1 2